CSN6基因在肝细胞癌组织中的表达及临床意义

doi:10.11904/j.issn.1002-3070.2019.04.008

摘要/Abstract

摘要： 目的探索组成型光形态发生因子9信号复合体亚基6(CSN6)在肝细胞癌中的表达及其在患者临床病理因素和预后方面的意义。方法利用公共数据库人类蛋白质图谱数据库和StarBase数据库分析CSN6在肝细胞癌和正常肝脏组织中的蛋白和mRNA的表达情况。利用TCGA数据库分析CSN6在不同肿瘤分期和分级的肝细胞癌患者中的表达差异。利用免疫组化方法检测106例肝细胞癌患者组织中CSN6的蛋白表达,分析其与多项临床病理因素和总生存期的关系。结果与正常肝脏组织相比,CSN6在肝细胞癌组织中的表达升高。CSN6在高病理分级(G3和G4)以及高分期(Ⅱ期和Ⅲ期)的患者中的表达更高;CSN6高表达的肝细胞癌患者的总生存期更短。CSN6在肝细胞癌中的表达与肿瘤分化程度和乙肝病毒感染具有相关性,并且是影响患者总生存期的独立预测因素。结论肝细胞癌中CSN6的表达显著升高,肝细胞癌患者组织中CSN6表达升高提示患者预后不良,其表达升高与肝细胞癌的恶性进展相关,有潜力成为一个新的预测预后的标志物以及治疗靶点。

关键词: CSN6, 肝细胞癌, 预后

Abstract: Objective The aim of this study was to explore the expression of constitutive photomorphogenesis factor 9 signaling complex subunit 6(CSN6)in hepatocellular carcinoma(HCC),and its clinicopathological factors and prognosis.Methods The expression of CSN6 at levels of protein and mRNA in hepatocellular carcinoma and normal hepatic tissues was analyzed using public human protein Atlas database and StarBase database.The TCGA database was used to analyze the differential expression of CSN6 in patients with different tumor stages and graded of hepatocellular carcinoma.Immunohistochemistry was used to detect the expression of CSN6 protein in 106 patients with HCC and analyzed its relationship with multiple clinicopathological factors and overall survival.Results The expression of CSN6 was elevated in hepatocellular carcinoma tissues when compared to normal hepatic tissues.CSN6 was more highly expressed in patients with high pathological grades(G3 and G4)and high stages (Ⅱ and Ⅲ);patients with hepatocellular carcinoma with high expression of CSN6 had a shorter overall survival.The expression of CSN6 in hepatocellular carcinoma was associated with tumor differentiation and hepatitis B virus infection,and was an independent predictor of overall survival.Conclusion The expression of CSN6 is significantly increased in hepatocellular carcinoma.The increased expression of CSN6 in HCC tissues suggests a poor prognosis.The increased expression is associated with the malignant progression of hepatocellular carcinomaand has a potential new prognostic marker and therapeutic target.

Key words: CSN6, Hepatocellular carcinoma, Prognosis

中图分类号:

R735.7

曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.

QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance[J]. Journal of Practical Oncology, 2019, 33(4): 328-333.

参考文献

1 Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
2 陈万青,邹小农,张思维.中国肝癌死亡率地理分布分析[J].实用肿瘤学杂志,2008,22(3):201-203.
3 Altekruse SF,McGlynn KA,Reichman ME.Hepatocellular carcinoma incidence,mortality,and survival trends in the United States from 1975 to 2005[J].J Clin Oncol,2009,27(9):1485-1491.
4 傅斌生,刘炜,张剑文,等.肝细胞肝癌患者血清和肝癌组织中fibulin-1 蛋白的表达及其临床意义[J].中华肝脏外科手术学电子杂志,2013,2(3):175-179.
5 Wei N,Deng XW.The COP9 signalosome[J].Annu Rev Cell Dev Biol,2003,19:261-286.
6 Sha Z,Yen HC,Scheel H,et al.Isolation of the Schizosaccharomyces pombe proteasome subunit Rpn7 and a structure-function study of the proteasome-COP9-initiation factor domain[J].J Biol Chem,2007,282(44):32414-32423.
7 Kotiguda GG,Weinberg D,Dessau M,et al.The organization of a CSN5-containing subcomplex of the COP9 signalosome[J].J Biol Chem,2012,287(50):42031-42041.
8 Wang W,Tang M,Zhang L,et al.Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer[J].Jpn J Clin Oncol,2013,43(12):1170-1176.
9 Fang L,Lu W,Choi HH,et al.ERK2-dependent phosphorylation of CSN6 is critical in colorectal cancer development[J].Cancer Cell,2015,28(2):183-197.
10 Hou J,Deng Q,Zhou J,et al.CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR[J].Oncogene,2017,36(8):1134-1144.
11 Gao S,Fang L,Phan LM,et al.COP9 signalosome subunit 6(CSN6)regulates E6AP/UBE3A in cervical cancer[J].Oncotarget,2015,6(29):28026-28041.
12 Uhlen M,Zhang C.A pathology atlas of the human cancer transcriptome[J].Science,2017,357(6352):2507.
13 Uhlen M,Fagerberg L,Hallstrom BM,et al.Proteomics.Tissue-based map of the human proteome[J].Science,2015,347(6220):1260419.
14 Li JH,Liu S,Zhou H,et al.starBase v2.0:decoding miRNA-ceRNA,miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data[J].Nucleic Acids Res,2014,42(Database issue):92-97.
15 Cerami E,Gao J,Dogrusoz U,et al.The cBio cancer genomics portal:an open platform for exploring multidimensional cancer genomics data[J].Cancer Discov,2012,2(5):401-404.
16 Liu C,Shi J,Li Q,et al.STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer[J].Clin Sci(Lond),2019,133(5):645-663.
17 Njei B,Rotman Y,Ditah I,et al.Emerging trends in hepatocellular carcinoma incidence and mortality[J].Hepatology,2015,61(1):191-199.
18 Utsunomiya T,Shimada M,Imura S,et al.Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma[J].J Gastroenterol,2010,45(2):146-152.
19 Choi HH,Lee MH.CSN6-COP1 axis in cancer[J].Aging(Albany NY),2015,7(7):461-462.
20 Salmena L,Hakem R.From photomorphogenesis to cancer:a CSN journey[J].Cell Cycle,2013,12(2):205-206.
21 Zhao R,Yeung SC,Chen J,et al.Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers[J].J Clin Invest,2011,121(3):851-865.
22 Chen J,Shin JH,Zhao R,et al.CSN6 drives carcinogenesis by positively regulating Myc stability[J].Nat Commun,2014,5:5384.
23 Chen B,Zhao R,Su CH,et al.CDK inhibitor p57(Kip2)is negatively regulated by COP9 signalosome subunit 6[J].Cell cycle,2012,11(24):4633-4641.

[1]	刘金涛, 高玲, 周会会. MAGEA4和EB1蛋白在肺癌组织中的表达及其与临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(4): 334-339.
[2]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[3]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[4]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[5]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[6]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[7]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[8]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[9]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[10]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[14]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[15]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.